title: Pharmacokinetics of Metronidazole in pregnant women.
abstract: Pharmacokinetic characteristics of metronidazole were studied in 19 pregnant women with Trichomoniasis urogenitalis who had been hospitalized for legal abortion. All patients received 250 mg or 1.0 g metronidazole (Vagimid) per os in a single or multiple dose. Peak levels were reached 1-2 h after application. Mean serum levels of metronidazole were somewhat lower in gravidae than those in nonpregnant women. The mean elimination half-life values were 5.7 and 7.7 h after intake of 250 mg and 1.0 g metronidazole, respectively. As suggested by our pharmacokinetic results, the dosage regimen for treatment of anaerobic bacteria infection or parasitic infection in pregnant women can be the same as in nonpregnant patients.
mesh_terms: D001798:Blood Proteins / Q000378:metabolism; D005260:Female; D006801:Humans; D007700:Kinetics; D008795:Metronidazole / Q000378:metabolism* / Q000627:therapeutic use; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy / Q000378:metabolism*; D011485:Protein Binding; D014245:Trichomonas Infections / Q000188:drug therapy
chemical_list: D001798:Blood Proteins; D008795:Metronidazole